Response to low dose temozolomide in radiation induced gliomatosis cerebri.
Hargrave
D
D
New Agent and Innovative Therapy Program, Hospital for Sick Children, Toronto, Canada. darren.hargrave@sickkids.ca
Bouffet
E
E
Gammon
J
J
Becker
L
L
Rutka
J
J
Baruchel
S
S
D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015448:Leukemia, B-Cell / Q000188:drug therapy / Q000532:radiotherapy; D008279:Magnetic Resonance Imaging; D018302:Neoplasms, Neuroepithelial / Q000188:drug therapy* / Q000473:pathology; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy* / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000532:radiotherapy; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide